Biosimilar denosumab was estimated to be cost-effective compared with alendronate, risedronate, ibandronate, and zoledronic acid at a WTP threshold of 150, 000/QALY gained and compared with risedronate at a threshold of 100, 000/QALY gained. As a lower-cost alternative to reference denosumab, biosimilar denosumab may enhance patient access to effective PMO treatment in the USA.
Flanigan et al. (Tue,) studied this question.